Down 33.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Lyell Immunopharma (LYEL)
Lyell Immunopharma Announces Participation in May Investor Conferences
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026
Lyell Immunopharma, Inc. (NASDAQ:LYEL) Sees Significant Increase in Short Interest
Lyell Immunopharma, Inc. (LYEL) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript
Lyell Immunopharma Announces Participation in 25th Annual Needham Virtual Healthcare Conference
Head to Head Analysis: Lyell Immunopharma (NASDAQ:LYEL) & Mangoceuticals (NASDAQ:MGRX)
Lyell Immunopharma: Strong Early CAR-T Data, And Now A More Measured Bet
Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results
Market Today: Oil Swings, Oracle Pops; Meta Buys Bot Network
Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer
Lyell Immunopharma, Inc. (LYEL) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Lyell Immunopharma Announces Participation in March Investor Conferences
Lyell Immunopharma Announces Initiation of Patient Dosing in First-of-Its-Kind Phase 3 Head-To-Head CAR T-Cell Clinical Trial in Aggressive Large B-Cell Lymphoma
Lyell Immunopharma (NASDAQ:LYEL) Stock Price Down 4.6% – Here’s What Happened
Lyell Immunopharma (NASDAQ:LYEL) Trading Down 6.7% – Should You Sell?
The Zacks Analyst Blog Mineralys, Lyell, Insmed and Nektar
Critical Review: Lipocine (NASDAQ:LPCN) & Lyell Immunopharma (NASDAQ:LYEL)
4 Drug, Biotech Stocks Rising More Than 50% in 2025 With Room to Grow
Lyell Immunopharma: LYL314 Drives Momentum Amid Strong ASH Data
Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market Surge
Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition
Lyell Immunopharma (NASDAQ:LYEL) Sets New 12-Month High – Here’s What Happened
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2025
Lyell Immunopharma Acquires Exclusive Global Rights to a Next-Generation CAR T-Cell Product Candidate in Clinical Development for Metastatic Colorectal Cancer
Lyell Announces Two Oral Presentations from the Phase 1/2 Clinical Trial of Ronde-Cel for the Treatment of Aggressive Large B-Cell Lymphoma at the 67th ASH Annual Meeting and Exposition
Lyell Immunopharma Announces the Initiation of a Phase 3 Head-to-Head CAR T-Cell Therapy Clinical Trial in Aggressive Large B-Cell Lymphoma and Formation of Expert Steering Committee
Lyell Immunopharma Announces Participation in September Investor Conferences
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2025
Lyell Immunopharma Announces up to $100 Million Equity Private Placement
Lyell: 'Hold' Rating Based On Phase 3 LYL314 LBCL Treatment Program Advancement
Lyell Immunopharma to Participate in the H.C. Wainwright “HCW@Home” Series
Lyell Immunopharma Announces Positive New Clinical Data Demonstrating High Rates of Durable Complete Responses from the Phase 1/2 Trial of LYL314 for the Treatment of Aggressive Large B-cell Lymphoma
Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments
Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2025
Lyell Immunopharma Announces Oral Presentation of New Clinical Data from the Phase 1/2 Trial of LYL314 for the Treatment of Large B-cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) 2025
Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for LYL314 for the Treatment of Relapsed and/or Refractory Large B-Cell Lymphoma
Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2024
Lyell Immunopharma Announces Participation in Upcoming Investor Conferences
Lyell Immunopharma (LYEL) Upgraded to Strong Buy: Here's Why
Lyell to Highlight Vision for its Next-Generation CAR T-Cell Therapy Pipeline at 43rd Annual JP Morgan Healthcare Conference
After Plunging -37.9% in 4 Weeks, Here's Why the Trend Might Reverse for Lyell Immunopharma (LYEL)
After Plunging -31.22% in 4 Weeks, Here's Why the Trend Might Reverse for Lyell Immunopharma (LYEL)
Down -30.89% in 4 Weeks, Here's Why Lyell Immunopharma (LYEL) Looks Ripe for a Turnaround
Lyell Presents Positive Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the Treatment of B-cell Lymphoma at the 2024 ASH Annual Meeting
Lyell Immunopharma (LYEL) Upgraded to Buy: Here's What You Should Know
Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting
Lyell Immunopharma Completes Acquisition of ImmPACT Bio